Publication Name	World Journal of Gastroenterology
Manuscript ID	4161
Country	Israel

Received	2013-06-17 19:46
Peer-Review Started	2013-06-18 16:55
First Decision by Editorial Office Director
Return for Revision	2013-07-20 22:57
Revised	2013-08-19 21:15
Publication Fee Transferred
Second Decision by Editor	2013-09-03 14:32
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-09-04 07:43
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-05 19:35
Publish the Manuscript Online	2013-12-18 10:00

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Autobiography
Article Title	Metastatic type 1 gastric carcinoid: A real threat or just a myth?
Manuscript Source	Invited Manuscript
All Author List	Simona Grozinsky-Glasberg, Dimitrios Thomas, Jonathan R Strosberg, Ulrich-Frank Pape, Stephan Felder, Apostolos V Tsolakis, Krystallenia I Alexandraki, Merav Fraenkel, Leonard Saiegh, Petachia Reissman, Gregory Kaltsas and David J Gross
Funding Agency and Grant Number
Corresponding Author	Dr. Simona Grozinsky-Glasberg, MD, Neuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, PO Box 12000, 91120 Jerusalem, Israel. simonag@hadassah.org.il
Key Words	Metastatic gastric carcinoids; Gastrin; Chromogranin A; Somatostatin analogues; Stomach neuroendocrine tumor
Core Tip	Metastatic gastric carcinoid type 1 (GCA1) are extremely rare and there is no data regarding their natural history, treatment and prognosis. Based on our study, metastatic GCA1 carries a good overall prognosis. Metastatic spread appears to be related to a tumor size of ≥ 1 cm, an elevated Ki-67 index, and to high serum gastrin levels. Endoscopic surveillance is extremely important for follow-up. Surgical resection should be performed only in patients in whom total tumor excision is expected. Although still controversial, somatostatin analogues could be considered as first line treatment to lower the elevated gastrin levels and suppress enterochromaffin like cell hyperplasia.
Publish Date	2013-12-18 10:00
Citation	Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: A real threat or just a myth? World J Gastroenterol 2013; 19(46): 8687-8695
URL	http://www.wjgnet.com/1007-9327/full/v19/i46/8687.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i46.8687

Full Article (PDF)	WJG-19-8687.pdf
Manuscript File	4161-Review.doc
Answering Reviewers	4161-Answering reviewers.pdf
Copyright License Agreement	4161-Copyright assignment.pdf
Peer-review Report	4161-Peer review(s).pdf
Scientific Editor Work List	4161-Scientific editor work list.doc